

Clinical trials of linagliptin + pioglitazone

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
linagliptin + pioglitazone vs pioglitazone			
linagliptin 1264.3 <i>ongoing</i> [NCT01183013] n=NA follow-up: 30 weeks	linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) linagliptine versus pioglitazone	-	

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

References

linagliptin 1264.3, 0:

ongoing trial NCT01183013

Entry terms: linagliptin, Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356,